What's Happening?
Circio Holding and Avenue Biosciences have entered a research collaboration to enhance the long-term expression of secreted proteins, which could benefit a wide range of diseases. The partnership combines Circio's circVec platform, known for driving durable
protein expression, with Avenue's protein engineering technology, which improves protein secretion. The collaboration aims to increase protein output per dose, potentially reducing the complexity and cost of gene therapies. This initiative could open new treatment opportunities beyond classical gene therapy for monogenic diseases.
Why It's Important?
The collaboration between Circio and Avenue Biosciences addresses a significant challenge in gene therapy: insufficient protein expression. By enhancing protein secretion, the partnership aims to improve the efficacy and accessibility of gene therapies, potentially benefiting patients with genetic and chronic diseases. This research could lead to more effective treatments with lower doses, reducing manufacturing complexity and costs. The collaboration highlights the importance of innovative approaches in gene therapy and the potential for technological synergies to advance medical treatments.
